At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, HUTCHMED presented the first clinical data from its successful Phase III SACHI study conducted in China investigating HCM’s savolitinib in combination with AstraZeneca’s Tagrisso (osimertinib) in second line non-small cell lung cancer (NSCLC). Ahead of the data release, market attention was particularly focused on progression-free survival (PFS) and the corresponding hazard ratios (HRs), which measure the relative risk of d ....
